“South Africa has unveiled a groundbreaking approach to breast cancer treatment through theranostics, a nuclear medicine innovation that integrates precise diagnosis with targeted therapy. This development, backed by a R3-million Harry Oppenheimer Fellowship Award, could shift breast cancer from a deadly disease to a manageable condition.”
Breast cancer remains the leading cancer among women in South Africa, accounting for thousands of diagnoses annually. Despite advances in oncology, 67% of patients are diagnosed at late stages, drastically reducing survival rates. Today, however, a new frontier in nuclear medicine—theranostics—is offering hope for a radical transformation in outcomes.
What is Theranostics?
Theranostics is a fusion of therapy and diagnostics, enabling doctors to detect cancer cells at the molecular level and simultaneously deliver targeted treatment. Unlike conventional chemotherapy or radiation, which often harm healthy tissue, theranostics pinpoints malignant cells with precision.
- Early detection: Identifies tumors at microscopic stages.
- Personalized treatment: Tailors therapy to individual patients.
- Continuous monitoring: Tracks response to treatment in real time.
Professor Mike Sathekge, head of Nuclear Medicine at the University of Pretoria and Steve Biko Academic Hospital, explains: “The earlier the breast cancer is detected, the more accurately it is assessed and the more precise the treatment, the exponentially better the patient’s prognosis.”
The Fellowship Award
Sathekge’s research has been recognized with the 2025 Harry Oppenheimer Fellowship Award, granting him R3 million to advance theranostics. This award is one of South Africa’s most prestigious academic honors, underscoring the national importance of his work.
The Public Health Context
South Africa’s public health system faces mounting challenges:
- Late-stage diagnoses: Two-thirds of breast cancer patients present with metastasis.
- Rising cancer burden: Driven by population growth, aging, and lifestyle changes.
- Resource constraints: Limited access to advanced oncology services in rural areas.
This breakthrough could bridge the gap between cutting-edge science and public health needs, ensuring equitable access to lifesaving technology.
Global Comparisons
Theranostics has already shown promise in Europe and North America, particularly in prostate cancer treatment. South Africa’s adoption for breast cancer positions the country as a continental leader in nuclear medicine innovation.
Potential Impact
- Survivability: Could reduce mortality rates by enabling earlier, more effective interventions.
- Healthcare efficiency: Streamlines diagnosis and treatment, reducing hospital burden.
- Economic benefits: Prevents productivity loss by keeping more women healthy and active.
Challenges Ahead
Despite optimism, several hurdles remain:
- Infrastructure: Theranostics requires advanced imaging facilities, currently limited to major hospitals.
- Training: Specialists in nuclear medicine are scarce in South Africa.
- Funding: Sustained investment is needed to scale nationwide.
Voices from the Field
Health Minister Aaron Motsoaledi has emphasized the importance of integrating theranostics into the public health system, noting that equitable access must be prioritized. Patient advocacy groups have also welcomed the innovation, calling it a “game-changer” for women’s health.
Conclusion
South Africa’s theranostics breakthrough represents a turning point in public health. By merging diagnosis and treatment, it offers a pathway to transform breast cancer from a deadly disease into a manageable condition. If successfully scaled, this innovation could save thousands of lives and cement South Africa’s role as a leader in global cancer research.
